Strain Profile
Save
Saccharomyces cerevisiae CNCM I-3856
◐
Food-origin
Where this strain was first isolated, curated from the literature and culture-collection catalogs. It describes provenance only — not suitability, and not benefit.
How we classify this →
Sequenced
Whether a public genome assembly is linked for this strain. Without one the genome screens cannot run. It is not a verdict on the organism.
How we classify this →
Public genome assembly available
Saccharomyces cerevisiae CNCM I-3856 is a probiotic yeast strain with multiple randomized controlled trials and a published meta-analysis focused on irritable bowel syndrome (IBS). The clinical evidence, including an individual-subject meta-analysis, has examined abdominal pain and digestive discomfort in IBS populations. In vitro studies have also explored its competitive interactions with enteropathogens such as E. coli O157:H7, and animal model work has examined inflammatory pathways in colitis models. This strain should not be viewed as a treatment for IBS or any other gastrointestinal condition. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 37 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 27 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
+3 more symptoms
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
43 papers reference this strain in the probiotic database.
Match confidence
How strongly this paper was matched to this strain when the corpus was linked. It orders the list — it says nothing about the study's quality or its findings.
How we classify this →
2023
ANIMAL
2022
ANIMAL
2022
ANIMAL
2022
ANIMAL
2021
IN_VITRO
2020
RCT
2019
RCT
2019
ANIMAL
2017
META_ANALYSIS
2015
IN_VITRO
2015
RCT
2015
ANIMAL
2015
ANIMAL
2015
ANIMAL
2015
ANIMAL
2015
RCT
2014
IN_VITRO
2014
IN_VITRO
2012
RCT
2012
IN_VITRO
Browse all 43 papers →
Saccharomyces cerevisiae prevents postoperative recurrence of Crohn's disease modeled by ileocecal resection in HLA-B27 transgenic rats
· World Journal of Gastroenterology
Avaliação do efeito probiótico de Saccharomyces cerevisiae CNCM I- 3856 na resposta inflamatória induzida experimentalmente por Salmonella enterica subsp. enterica sorovar Typhimurium
· LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Stratégies de prévention de la récidive post-opératoire après résection iléo-caecale pour maladie de Crohn dans le modèle du rat transgénique HLA-B27
·
Strategies for preventing postoperative recurrence of Crohn's disease after ileocecal resection in the transgenic HLA B27 rat model
· Munich Personal RePEc Archive (Ludwig Maximilian University of Munich)
Multi-targeted properties of the probiotic saccharomyces cerevisiae CNCM I-3856 against enterotoxigenic escherichia coli (ETEC) H10407 pathogenesis across human gut models
· Gut Microbes
Recovery of Saccharomyces cerevisiae CNCM I-3856 in Vaginal Samples of Healthy Women after Oral Administration
· Nutrients
Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome
· International Journal of Colorectal Disease
Saccharomyces cerevisiae CNCM I-3856 as a New Therapeutic Agent Against Oropharyngeal Candidiasis
· Frontiers in Microbiology
Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis
· World Journal of Gastroenterology
Dynamic In Vitro Models of the Human Gastrointestinal Tract as Relevant Tools to Assess the Survival of Probiotic Strains and Their Interactions with Gut Microbiota
· Microorganisms
Saccharomyces cerevisiae CNCM I-3856: A new strategy to improve abdominal pain/digestive discomfort
· Europe PMC (PubMed Central)
Prophylactic and therapeutic strategies to limit Adherent-Invasive Escherichia coli (AIEC) in the digestive tract in the context of Chron's disease
· theses.fr (ABES)
Stratégies prophylactiques et thérapeutiques visant à limiter les Escherichia coli Adhérents-Invasifs (AIEC) du tractus digestif dans le contexte de la maladie de Crohn
· HAL (Le Centre pour la Communication Scientifique Directe)
Saccharomyces cerevisiae CNCM I-3856 Prevents Colitis Induced by AIEC Bacteria in the Transgenic Mouse Model Mimicking Crohnʼs Disease
· Inflammatory Bowel Diseases
Stratégies thérapeutiques visant à limiter les E.coli Adhérents-Invasifs du tractus digestif dans le cadre de la Maladie de Crohn.
· theses.fr (ABES)
Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation
· United European Gastroenterology Journal
Study of the survival and pathogenicity of enterohemorrhagic Escherichia coli (EHEC) in artificial digestive systems . Influence of the food matrix and of the administration of probiotic strains.
· theses.fr (ABES)
Etude en systèmes digestifs artificiels de la survie et de la pathogénicité des Escherichia Coli entérohémorragiques (EHEC). Influence de la matrice alimentaire et de l'administration de souches probiotiques.
·
A double‐blind, randomized, controlled clinical study to evaluate the properties of Saccharomyces cerevisiae CNCM I‐ 3856 on Irritable Bowel Syndrome management
· The FASEB Journal
Enterohemorrhagic Escherichia coli O157:H7 Survival in an In Vitro Model of the Human Large Intestine and Interactions with Probiotic Yeasts and Resident Microbiota
· Applied and Environmental Microbiology
Discussion
Be the first to comment.
Sign in to join the discussion.
No comments yet.
Citations
Selected papers that name this strain.
-
[1]
PMID 41682832 →Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome· Journal of Clinical Medicine · 2026
-
[2]
PMID 32722250 →Recovery of Saccharomyces cerevisiae CNCM I-3856 in Vaginal Samples of Healthy Women after Oral Administration· Nutrients · 2020
-
[3]
PMID 28127207 →Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis· World Journal of Gastroenterology · 2017
-
[4]
PMID 27403301 →Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation· United European Gastroenterology Journal · 2015
-
[5]
Source →A double‐blind, randomized, controlled clinical study to evaluate the properties of Saccharomyces cerevisiae CNCM I‐ 3856 on Irritable Bowel Syndrome management· The FASEB Journal · 2012